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Abstract: The DNA damage response (DDR) is a designation for a number of pathways that protects
our DNA from various damaging agents. In normal cells, the DDR is extremely important for
maintaining genome integrity, but in cancer cells these mechanisms counteract therapy-induced
DNA damage. Inhibition of the DDR could therefore be used to increase the efficacy of anti-cancer
treatments. Hyperthermia is an example of such a treatment—it inhibits a sub-pathway of the
DDR, called homologous recombination (HR). It does so by inducing proteasomal degradation of
BRCA2 —one of the key HR factors. Understanding the precise mechanism that mediates this
degradation is important for our understanding of how hyperthermia affects therapy and how
homologous recombination and BRCA2 itself function. In addition, mechanistic insight into the
process of hyperthermia-induced BRCA2 degradation can yield new therapeutic strategies to enhance
the effects of local hyperthermia or to inhibit HR. Here, we investigate the mechanisms driving
hyperthermia-induced BRCA2 degradation. We find that BRCA2 degradation is evolutionarily
conserved, that BRCA2 stability is dependent on HSP90, that ubiquitin might not be involved in
directly targeting BRCA2 for protein degradation via the proteasome, and that BRCA2 degradation
might be modulated by oxidative stress and radical scavengers.
Keywords: hyperthermia; homologous recombination; BRCA2; RAD51; ubiquitin; SILAC mass
spectrometry; reactive oxygen species; protein degradation; HSP90
1. Introduction
The DNA damage response (DDR) consists of various intricate pathways that maintain the
integrity of the DNA in our cells, which is continuously threatened by endogenous and exogenous
agents [1–3]. The DDR deals with DNA damage inflicted by these assaults by detecting its presence,
signaling to the pathways controlling cell cycle progression, and finally repairing or bypassing the
damage [2]. However, the protection provided by the DDR has justly been described as a double-edged
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sword—by safeguarding the DNA, it prevents accumulation of mutations in genes that might lead to
cancer, but also counteracts the efficacy of many anti-cancer therapies that are based on the cytotoxicity
of DNA damage [4]. It is because of the latter aspect that inhibition of the DDR is of great interest in
the context of cancer treatment [5].
The importance of the DDR for treatment efficacy is illustrated by tumors harboring defects in a
specific pathway of the DDR, such as homologous recombination (HR), examples of which are breast
and ovarian tumors with BRCA1 and BRCA2 mutations. These tumors are not only very sensitive to
specific chemotherapeutics such as cisplatin and carboplatin [6,7], but also to a new class of drugs,
inhibitors of poly [ADP-ribose] polymerase 1 (PARP-1) [8–10]. PARP-1 inhibitors have been used to
target the DDR in clinical practice [11], and are an example of precision treatment—while normal cells
can compensate for a deficiency in DDR-pathways involving PARP-1-related repair by using the HR
machinery, tumors that are HR-deficient cannot. Thus, the clinical efficacy of PARP-1 inhibitors in turn
makes HR an attractive therapeutic target—if one could inhibit HR in a tumor, it would become more
sensitive to these treatment modalities.
HR is one of the two pathways that repair DNA double-stranded breaks (DSBs), the other being
non-homologous end joining (NHEJ). While, in essence, NHEJ repairs DNA by directly re-joining the
two ends of a DSB together and is active throughout the cell cycle, HR faithfully restores DSBs by
using an intact copy of the DNA as a template. This copy is usually the sister chromatid that arises
during replication, which limits HR activity to the S and G2-phases of the cell cycle. HR is tightly
regulated, and involves an orchestrated series of events mediated by many different proteins [12]. The
start of the HR pathway is characterized by the generation of 3’ single-strand overhangs by DNA
end resection, a process mediated by BRCA1, among other proteins. Strand invasion—a central step
in the HR pathway—is catalyzed by the nucleoprotein filaments formed by RAD51 on the resected,
single-stranded DNA. The assembly of RAD51 onto the DNA is aided by many proteins, including
BRCA2 and RAD54 [13–15]. The invaded strand is now used as a template for repair of the resected
strands. Resolution of the holiday junctions is the last step of HR, and can have several outcomes;
however, in effect, all result in faithful repair of the broken DNA [12].
As a consequence of the complexity of HR, the pathway can be interfered with at multiple
levels to create a window of therapeutic opportunities [16–18]. However, when thinking about such
approaches, one should consider that HR is essential for cellular survival, and interfering with it
could have disastrous consequences in normal cells [19]. Ideally, inhibition of HR in cancer treatment
should occur in a local fashion. Hyperthermia is a method which has the potential to achieve exactly
this result—by locally applying heat to a tumor, it triggers a pathway which induces degradation of
BRCA2, resulting in a failure to localize RAD51 to DSBs and effectively attenuating HR [20]. BRCA2
degradation is rapidly (within ~15 minutes) induced by hyperthermia in a temperature range between
41–43 ◦C [21,22]. However, the molecular mechanisms of heat-mediated degradation of BRCA2 are
largely unknown, with the exception of the last step which involves the proteasome [21].
Here, we investigate the mechanisms that mediate BRCA2 degradation upon heating, because this
could yield: (1) a better understanding of the effects of hyperthermia; (2) an increased understanding
of the modulation of the HR pathway and of the BRCA2 protein itself; (3) new therapeutic approaches
to inhibit HR, and; (4) therapeutic targets that may enhance the local effects of hyperthermia.
2. Results
2.1. Heat-Mediated Degradation of BRCA2 and Modulation of HR
Hyperthermia induces BRCA2-degradation in established human cell lines of different origins,
and in human tumors heated ex vivo [21,23,24]. The reduction in BRCA2 levels has been detected using
the OP95 BRCA2 antibody. To confirm that the observed decline in BRCA2 protein levels is not due
to changes in availability of the epitope detected by the antibody, we exposed HeLa cells expressing
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BRCA2, tagged with the FLAG epitope (DYKDDDDK), to 42 ◦C for one hour, and were able to detect a
heat-induced reduction in the BRCA2 level with the FLAG-specific M2 antibody (Figure 1A).
The 3328-aa mouse BRCA2 shares 59% amino acid identity with its human orthologue [25]. To
determine whether murine BRCA2 is also susceptible to degradation upon hyperthermia treatment,
we exposed wild-type (IB10) and Brca2GFP/GFP [26] mouse embryonic stem cells (mES) to hyperthermia.
Because the OP95 antibody has been raised against amino acids 1651-1821 of human BRCA2—a
region poorly conserved in murine BRCA2 [25]—we immunoblotted with a polyclonal antibody
(ab27976) recognizing the conserved N-terminus of BRCA2 and with an anti-Green Fluorescence
Protein (GFP)antibody. We found that both murine BRCA2 and murine BRCA2-GFP were degraded
upon hyperthermia, indicating that the heat-mediated response is evolutionarily conserved (Figure 1B).
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2.2. Various Inhibitors Affect Heat-Mediated BRCA2 Degradation
Thermal stress generally causes protein unfolding, and it is likely that the BRCA2 protein shares
this fate. Cells can deal with unfolded proteins by either refolding them with the aid of molecular
chaperones, or, if a protein cannot be rescued, breaking it down. Two separate systems for protein
degradation are currently recognized: the ubiquitin-proteasome pathway and lysosomal degradation
(autophagy), the latter being primarily associated with processing large and aggregated proteins [27].
Heat-induced degradation of BRCA2 seems to proceed via the proteasome [21], and we could
indeed confirm that the proteasome inhibitor MG132 stops this process (Figure 2A). In contrast, we
found that bafilomycin A1, an inhibitor of a late step in autophagy [28], did not protect BRCA2
from degradation (Figure 2B), indicating that BRCA2 is exclusively degraded via the proteasome.
3-[3-(Cyclopentylthio)-5-[[[2-methyl-4′-(methylsulfonyl)[1,1′-biphenyl]-4-yl]oxy]methyl]-4H-1,2,4-
triazol-4-yl]-pyridine, 3-[3-Cyclopentylsulfanyl-5-(4′-methanesulfonyl-2-methylbiphenyl-4-yloxymethyl)-
[1,2,4]triazol-4-yl]-pyridin (NMS-873), which inhibits valosin-containing protein (VCP; also known as
p97 or CDC48), a “segragase” acting in many cellular processes—including extraction of ubiquitinated
proteins from chromatin and membranes [29]—also protected BRCA2 from degradation (Figure 2C).
BRCA2 is thought to be a client protein of the molecular chaperone HSP90, and a prolonged
inhibition of HSP90 causes reduction in BRCA2 levels [30]. As expected, inhibition of HSP90 indeed
enhanced BRCA2 degradation upon hyperthermia (Figure 2D) [21,31]. To test the importance of
renewed synthesis of BRCA2 during hyperthermia treatment, we treated cells with the translation
inhibitor cycloheximide. Surprisingly, we found that inhibition of translation protected BRCA2 from
degradation (Figure 2E). This protection expired after two hours of treatment, which indicates that
translation is important to maintain BRCA2 protein levels (Figure 2F).
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treated with or without 60 min of hyperthermia in the presence of indicated doses of different inhibitors.
All inhibitors were added 30–60 min prior to hyperthermia treatment. (A) Human Bone Osteosarco a
U2OS cells treated with the proteasome inhibitor MG132. (B) HeLa cells treated with the autophagy
inhibitor bafilomycin A1. (C) U2OS cells treated with an inhibitor of the v losin-containing protein
(VCP) segregase. (D) U2OS cells treated with the HSP90 inhibitor, ganetespib. (E) Lymphoma-derived
BRO cells treated with the translation inhibitor, cycloheximide. (F) BRO cells treat d with cycloheximide
(50 µg/mL) and hyperthermia for the indicated periods of time. (G) U2OS cells were treat d with or
without hyperth rmia in the presence of dimethylsulfoxide (DMSO) and cycloheximide, irradiated
with 5 Gy, an fixed 90 min after irradiation. C lls were stain d for 5-e hynyl-2’-deoxyuridi (EdU)
and the protein product of the R dia ion 51 RAD51 gene. The panel shows the RAD51-staining for
representative cells for each c ndition. The dotted line indicates the perimeter of an EdU-positive
nucleus. Numbers in the panel indi ate the mean number of foci ± standard error of the ean and the
number of cells analyzed.
To determine whether or not the fraction of BRCA2 protected by the different inhibitors was
still functional, we tested for focus formation of the protein product of the Radiation 51 RAD51 gene
(Figure 2G). Formation of RAD51 foci upon irradiation is strictly dependent on BRCA2 [13,32] and has
been demonstrated to be abrogated by heat [21,22]. Both MG132 and VCP inhibition impair RAD51
focus formation [33,34], so we were able to perform this assay for cycloheximide only. Cycloheximide
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decreased the number of RAD51 foci in irradiated cells incubated at 37 ◦C, but treatment with heat
failed to enhance this effect, indicating that the abundance of BRCA2, as well as its functionality might
be protected by inhibition of translation.
2.3. BRCA2 Stability Is Dependent on HSP90
Targeting HSP90 by inhibitors like 17-Dimethylaminoethylamino-17-demethoxygeldanamycin
(17-DMAG) increase the extent of BRCA2 degradation upon hyperthermia [21]. We have shown that a
short exposure to the second-generation HSP90-inhibitor, ganetespib, achieves the same result and
increases the cells’ sensitivity to hyperthermia (Figure 2D) [31]. To further explore the extent by which
BRCA2-protein stability is dependent on HSP90 upon being challenged by hyperthermia, we combined
cycloheximide, ganetespib, and hyperthermia in a single experiment. We found that the protective
effects of cycloheximide on BRCA2 were at least partly dependent on HSP90 (Figure 3A). Moreover,
we found that the autophagy inhibitor bafilomycin did not rescue BRCA2 from the combination of
hyperthermia and ganetespib, while MG132 did (Figure 3B). This indicates that BRCA2 is cleared by
the proteasome in the presence of an HSP90 inhibitor and hyperthermia, as is the case for hyperthermia
alone (Figure 2A) [21]. All these results combined reinforce the hypothesis that HSP90 protects BRCA2
under hyperthermic conditions.
Cancers 2019, 11, x FOR PEER REVIEW  5 of 25 
 
a short exposure to the second-generation HSP90-inhibitor, ganetespib, achieves the same result and 
increases the cells’ sensitivity to hyperthermia (Figure 2D) [31]. To further explore the extent by which 
BRCA2-protein stability is dependent on HSP90 upon being challenged by hyperther ia, we 
combined cycloheximide, ganetespib, and hyperthermia in a single experiment. We found that the 
protective effects of cycloheximide on BRCA2 were at least partly dependent on HSP90 (Figure 3A). 
Moreover, we found that the autophagy inhibitor bafilomycin did not rescue BRCA2 from the 
combination of hyperthermia and ganetespib, while MG132 did (Figure 3B). This indicates that 
BRCA2 is cleared by the proteasome in the presence of an HSP90 inhibitor and hyperthermia, as is 
the case for hyperthermia alone (Figure 2A) [21]. All these results combined reinforce the hypothesis 
that HSP90 protects BRCA2 under hyperthermic conditions. 
 
Figure 3. BRCA2 is a client protein of HSP90. (A) Immunoblot of BRO cells treated with or without 
60 min of hyperthermia in the presence of cycloheximide (50 µg/mL), ganetespib (50 nM), or both. (B) 
Immunoblots of HeLa cells treated with or without hyperthermia in the presence of various 
combinations of proteasomal inhibitor MG132 (50 µM), autophagy inhibitor bafilomycin (10 nM), and 
HSP90-inhibitor ganetespib (50 nM). 
2.4. Searching for the Proteins that Mediate Degradation of BRCA2 upon Hyperthermia 
The cascade of events that leads to proteasomal degradation of BRCA2 upon heat treatment 
might involve (unknown) BRCA2 interaction partners, which could be interesting from both a 
biological and clinical perspective. Usually, a protein is post-translationally marked with ubiquitin 
before being degraded by the proteasome. Ubiquitination is mediated by a number of enzymes [35]. 
First, an E1-activating enzyme activates and transfers a ubiquitin molecule to the E2-conjugating 
enzyme. The E2-enzyme is recruited to an E3-ubiquitin ligase, which catalyzes the transfer of 
ubiquitin to a target lysine of the protein. Being the last in the ubiquitin-cascade, the E3-ligases 
provide the specificity to the target protein, and are therefore potentially the most interesting 
interaction partners. However, over 600 different E3-ligases have been identified thus far [36] and 
pinpointing the E3-ligases responsible for heat-mediated BRCA2 degradation is challenging. The 
number of known E2-conjugating enzymes is more manageable. Moreover, E2 enzymes can be used 
to identify their downstream partner, E3 ligase(s) [37]. Therefore, we set out to individually knock 
down all E2-conjugating enzymes by siRNA in U2OS cells (Figure 4A). However, downregulation of 
no single E2-conjugating enzyme protected BRCA2 from heat-induced degradation (Figure 4A). To 
Figure 3. BRCA2 is a client protein of HSP90. (A) Immunoblot of BRO cells treated with or without
60 min of rt resence of cycloheximide (50 µg/mL), gan tespib (50 nM), or both.
(B) Immun blots of HeLa cells treated with or ithout erther ia presence of various
combinations of proteasomal inhibitor MG132 (50 µM), autophagy inhibitor bafilomycin (10 nM), and
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2.4. Searching for the Proteins that Mediate Degradation of BRCA2 upon Hyperthermia
The cascade of events that leads to proteasomal degradation of BRCA2 upon heat treatment might
involve (unknown) BRCA2 interaction partners, which could be interesting from both a biological
and clinical perspective. Usually, a protein is post-translationally marked with ubiquitin before being
degraded by the proteasome. Ubiquitination is mediated by a number of enzymes [35]. First, an
E1-activating enzyme activates and transfers a ubiquitin molecule to the E2-conjugating enzyme. The
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E2-enzyme is recruited to an E3-ubiquitin ligase, which catalyzes the transfer of ubiquitin to a target
lysine of the protein. Being the last in the ubiquitin-cascade, the E3-ligases provide the specificity to the
target protein, and are therefore potentially the most interesting interaction partners. However, over
600 different E3-ligases have been identified thus far [36] and pinpointing the E3-ligases responsible
for heat-mediated BRCA2 degradation is challenging. The number of known E2-conjugating enzymes
is more manageable. Moreover, E2 enzymes can be used to identify their downstream partner, E3
ligase(s) [37]. Therefore, we set out to individually knock down all E2-conjugating enzymes by siRNA
in U2OS cells (Figure 4A). However, downregulation of no single E2-conjugating enzyme protected
BRCA2 from heat-induced degradation (Figure 4A). To test for redundancy between E2-enzyme
families, we combined siRNAs to simultaneously downregulate multiple E2-enzymes, but found
no effect on BRCA2 levels (Figure 4B). The small ubiquitin-like modifier (SUMO) is also able to
target proteins to the proteasome, and SUMOylation is increased upon heat-shock [38]. We therefore
downregulated the E2-conjugating enzyme for SUMO and UBC9 (also known as UBE2I) [39], but
found that this also had no effect on BRCA2 protein levels after hyperthermia (Figure 4C).
Because no candidate E2-conjugating enzymes emerged from the systematic screen, we decided
to try a candidate approach for several E3-ligases. The first E3-ligase we included, C terminus of
HSC70-Interacting Protein (CHIP; also known as STUB1), is involved in the heat-shock response [40],
cooperating with multiple E2-conjugating enzymes [41], and has been implicated in the degradation of
the base excision repair protein 8-Oxoguanine glycosylase (OGG1) upon hyperthermia [42]. However,
knockdown of CHIP did not affect BRCA2 degradation upon heat treatment (Figure 5A). Knockdown
of the four SUMO E3-ligases Protein Inhibitor Of Activated STAT (PIAS) 1-4 [43] did not affect BRCA2
protein levels (Figure 5B), and nor did the knockdown of two SUMO-targeted ubiquitin ligases
(STUbLs), RNF4 and RNF111 (also known as Arkadia), both implicated in DNA double-strand break
(DSB) signaling [39,44] (Figure 5C). We found that the absence of BRCA1, which is closely related to
the BRCA2 complex and which has E3-ligase activity [45–47], did not change degradation of BRCA2
upon hyperthermia (Figure 5D). Inhibition of the neddylation 8 (NEDD8)-activating Enzyme 1 (NAE1),
which prevents neddylation and thereby activation of all Cullin-type E3 ligases [48,49], also did
not affect BRCA2 degradation (Figure 5E). Finally, we abolished all ubiquitination by inhibiting the
E1-activating enzyme using PYR-41 [50] and, surprisingly, found that addition of this inhibitor failed
to protect BRCA2 upon applying hyperthermia, in contrast to the addition of a proteasome inhibitor
(Figure 5F).
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Figure 5. Searching for the E3-ligase that mediates degradation of BRCA2 upon hyperthermia. (A) Effect
of hyperthermia on BRCA2 levels upon knock-down of the Heat-shock Protein (HSP)-associated
E3-ligase, C terminus of HSC70-Interacting Protein (CHIP), in U2OS cells using two different siRNAs.
Arrow on the right next to the CHIP panel indicates the predicted position of the CHIP protein.
(B) Effect of hyperthermia on BRCA2 levels upon knock-down of the SUMO-E3 ligases Protein Inhibitor
Of Activated STAT( PIAS) 1-4 in U2OS cells using siRNAs. (C) Effect of hyperthermia on BRCA2
levels upon siRNA knock-down of DNA-repair-related, SUMO-targeted ubiquitin ligases, Ring Finger
(RNF) 4 and RNF111. (D) Detection of BRCA2 and BRCA1 in UWB1.289 (BRCA1-null) cells with
or without complementation of wild type BRCA1 (wtBRCA1). (E) Detection of BRCA2 in U2OS
cells treated with increased doses of the neddylation-inhibitor MLN4924, added 30 min prior to
hyperthermia. (F) Detection of BRCA2 in U2OS cells treated with or without hyperthermia in the
presence of proteasome inhibitor MG132 (10 µM) or the E1-activating enzyme inhibitor PYR-41 (10 µM).
Inhibitors were added 1 h prior to hyperthermia treatment, and left on for the duration of the treatment.
2.5. Heat-Mediated BRCA2 Degradation from the Protein’s Perspective
Since neither the E2-wide screen nor the E3-candidate approach yielded proteins involved in
mediating hyperthermia-induced BRCA2 degradation, we decided to approach the problem from the
perspective of BRCA2 itself (Figure 6A). This protein has a number of properties which complicate
various proteomic approaches in the presence of hyperthermia: BRCA2 is (1) large (384 kDa);
(2) expressed at a relatively low level and only during the S and G2 phase of the cell cycle [51,52];
(3) predicted to have many intrinsically disordered domains [53], and; (4) degraded upon treatment
with hyperthermia.
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In order to side-step some of the properties listed above, we started by engineering three fragments
of BRCA2: a fragment starting from the N-terminus (amino acids 1-939), a middle part (amino acids
940-2198), and a fragment ending in the C-terminus (amino acids 2199-3418) (Figure 6B). We tagged them
with either GFP (Figure 6C) or FLAG (Figure 6D) and introduced them to HeLa cells using a PiggyBac
transposon system [54]. We found that all GFP-tagged versions of the BRCA2-fragments displayed
some degradation upon hyperthermia, although at much reduced levels compared to endogenous
BRCA2 (Figure 6C). The degradation was most pronounced for BRCA2-Middle (Figure 6C), which we
also found when using a FLAG-tagged version (Figure 6D). We engineered a fourth FLAG-construct,
encoding the fused N-terminal and C-terminal parts of BRCA2 (∆Middle), and found that this fragment
was also degraded upon heat, in contrast to the separate FLAG-tagged N-terminal or C-terminal
fragments (Figure 6D). This observation, together with the difference in the extent of degradation of
BRCA2-fragments tagged with either GFP or FLAG, suggest that expression levels of the constructs
could potentially influence the results in this assay—overexpression of the fragments may saturate the
molecular components which mediate degradation.
To obtain more conclusive evidence for which part of BRCA2 is degraded upon hyperthermia, we
took advantage of the behavior of endogenous BRCA2. Since the protected BRCA2 is shifted to the
insoluble fraction of cell lysates [22], we subjected cells expressing BRCA2 fragments to hyperthermia
in the presence of MG132 and performed a simple fractionation using a mild detergent (Figure 6E).
We found that the FLAG-tagged full-length protein behaved identically to the untagged wild-type
BRCA2. Hyperthermia caused the BRCA2-protein to shift from a soluble fraction, and addition
of MG132 dramatically increased its presence in the insoluble fraction (Figure 6E) [22]. The same
localization of BRCA2 protein fragments in the supernatant and pellet was found in cells expressing
BRCA2-Middle, BRCA2-C-terminus, and BRCA2∆Middle (Figure 6E). Interestingly, the N-terminal
version of BRCA2 did not disappear from the supernatant upon treatment with hyperthermia alone,
but did so when MG132 was added (Figure 6E). Together, these results suggest that the Middle and
C-terminal fragments contain the major determinants for heat-mediated BRCA2 degradation, and
might therefore be of interest to identify heat-dependent interaction partners.
2.6. Semi-Quantitative Mass Spectrometry Analysis Identifies Putative BRCA2-Interactors upon Hyperthermia
In parallel to the previous approach, and as another way to investigate hyperthermia-mediated
degradation of BRCA2 from the protein’s perspective, we performed a proteomic analysis in Brca2GFP/GFP
mES cells [26], where BRCA2 was immunoprecipitated using GFP nanobody beads. A three-state
reciprocal Stable Isotope Labelling with Amino acids in Cell culture (SILAC) approach was used to
quantitatively compare three different treatments: 0, 20, and 60 min of hyperthermia at 42 ◦C. Log2
SILAC ratios were calculated for each protein, and revealed that 20 min exposure to hyperthermia
enriched the immunoprecipitate of BRCA2-GFP for Ubiquitin, USP28, and HSPB1 (also known as
HSP25 and HSP27) (Table 1). HSPB1 and USP28 remained enriched in the immunoprecipitate after
60 min of hyperthermia (Table 1). Hyperthermia induces BRCA2 degradation, and therefore the
decreased abundance of BRCA2, and known interactors such as RAD51 and PALB2 after 60 min at
42 ◦C can be regarded as a quality control within this experiment (Table 1).
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Table 1. GFP nanobody bead pull-down from Brca2GFP/GFP mES cells labelled for three-state Stable
Isotope Labelling with Amino acids in Cell culture (SILAC). Brca2GFP/GFP mES cells were labelled with
Light (L, K0R0), Medium (M, K4R6), and Heavy (H, K8R10) SILAC states. The cells were lysed in
immunoprecipitation buffer immediately after the exposure to 42 ◦C for 0, 20, or 60 min. Precipitated
proteins were separated by Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE)
and analyzed by mass spectrometry. The treated to untreated SILAC ratios from two independent
reciprocal label-swap experiments are given in the table, comparing 37 ◦C (“untreated”) with 20 min at
42 ◦C (“treated”) in the first column, and 37 ◦C with 60 min at 42 ◦C (“treated”) in the second.
Protein Peptides Coverage Maxquant Pep
20 Min HT 60 Min HT
Exp 1 Exp 2 Exp 1 Exp 2
BRCA2 211 65 0.0E + 00 1.20 0.90 0.28 0.53
PALB2 36 44.5 0.0E + 00 1.49 0.92 0.30 0.37
RAD51 16 57.5 0.0E + 00 1.24 0.57 0.18 0.22
BRCA1 19 12.9 2.5E − 58 1.25 1.39 0.15 0.83
KEAP1 21 39.6 3.5E − 164 1.42 1.02 0.29 0.42
MORF4L1 17 61.9 1.1E − 271 1.44 0.89 0.29 0.42
MORF4L2 11 43.1 2.2E − 78 1.47 0.79 0.71 0.49
Ubiquitin 8 56.4 8.3E − 87 3.42 4.60 4.06 3.54
HSPB1 10 67.9 4.3E − 69 1.45 2.26 3.19 1.87
USP28 6 6 1.0E − 12 1.61 3.75 1.00 2.74
% SILAC ratio treated to untreated
2.7. Oxidative Stress Induces BRCA2 Degradation
The proteomic experiment identified HSPB1 as a prominent addition to the BRCA2 interactome
shortly after hyperthermia (Table 1) and also confirmed the previously published observation that
Kelch-like ECH-associated protein 1 (KEAP1) is part of the BRCA2 complex [47]. Interestingly, both
proteins participate in the oxidative stress response [55,56]. This is of interest, because hyperthermia is
thought to alter the redox state of cells by inducing an imbalance between the production of reactive
oxygen species (ROS) and the presence of radical scavengers [57]. For instance, hyperthermia increases
ROS by upregulating nicotinamide adenine dinucleotide phosphate oxidase (NADPH oxidase) [58]
and has been implicated in downregulation of the antioxidant glutathione [59]. This prompted us to
investigate whether there was a connection between oxidative stress and BRCA2 protein stability.
To test the possible relation between heat-induced oxidative stress and BRCA2 degradation,
we first analyzed whether introduction of exogenous antioxidants could protect BRCA2 from being
degraded by hyperthermia. We found that the anti-oxidants N-acetylcysteine (NAC) [60] and ascorbic
acid at low concentrations protected BRCA2 in hyperthermic circumstances (Figure 7A). Dithiothreitol
(DTT), which reduces disulphide bonds of proteins, did not prevent BRCA2 degradation upon
hyperthermia, but lowered protein levels upon increased concentration under non-hyperthermic
conditions (Figure 7A).
Previously, it was found that ultraviolet B irradiation (UV-B) causes downregulation of BRCA2,
which was not dependent on cell cycle differences and could be blocked by cycloheximide [61]. In the
context of the relation between oxidative stress and BRCA2, this is of special interest because it has
been reported that UV-B induces ROS [62,63] and potentiates a disturbance in oxidative homeostasis.
We found that UV-B indeed downregulated BRCA2 (Figure 7B). Next, we added several compounds
that increased the amount of ROS in the cell, further disturbing the oxidative balance. While the
mitochondrial complex I inhibitor rotenone [64] and the organic peroxide tert-Butyl hydroperoxide
(t-BHP) did not clearly decrease BRCA2 protein levels, addition of H2O2 did (Figure 7C). Like
hyperthermia-induced degradation of BRCA2, inhibition of the proteasome protected BRCA2 from
H2O2-mediated degradation (Figure 7D). Failure of rotenone to induce BRCA2 degradation can be
explained by mitochondrial localization of the ROS it produces. Organic (t-BHP) and inorganic (H2O2)
peroxides are metabolized differently, and can have profoundly different effects on DNA integrity,
poly (ADP-ribose) polymerase (PARP) activation, and apoptosis induction [65–67]. In the context
of the relation between oxidative stress and BRCA2, this is of special interest because it has been
Cancers 2019, 11, 97 12 of 26
reported that UV-B induces ROS [61,62] and potentiates a disturbance in oxidative homeostasis. We
found that UV-B indeed downregulated BRCA2 (Figure 7B). Next, we added several compounds
that increased the amount of ROS in the cell, further disturbing the oxidative balance. While the
mitochondrial complex I inhibitor rotenone [63] and the organic peroxide tert-Butyl hydroperoxide
(t-BHP) did not clearly decrease BRCA2 protein levels, addition of H2O2 did (Figure 7C). Like
hyperthermia-induced degradation of BRCA2, inhibition (Figure 7D) of the proteasome protected
BRCA2 from H2O2-mediated degradation (Figure 7D). Failure of rotenone to induce BRCA2 degradation
can be explained by mitochondrial localization of the ROS it produces. Organic (t-BHP) and inorganic
(H2O2) peroxides are metabolized differently, and can have profoundly different effects on DNA
integrity, PARP activation, and apoptosis induction [64,66]. Which of these differences is responsible
for the distinct effects on BRCA2 requires further investigation.
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Figure 7. Oxidative stress as an inducer of BRCA2 degradation. (A) BRCA2 levels in BRO cells subjected
to hyperthermia in the presence of indicated doses of antioxidant compounds N-acetylcysteine (NAC),
ascorbic Acid (Asc), or dithiothreitol (DTT). (B) BRCA2 levels in BRO cells subjected to the indicated
dose of ultraviolet-B and lysed three hours afterwards. (C) BRCA2 levels in BRO cells treated with
various concentrations of oxidative stress-inducers H2O2, tert-Butyl hydroperoxide (t-BHP), and
Rotenone. (D) BRCA2 levels in BRO cells exposed to hyperthermia or H2O2 (0.1 mM) in the presence
or absence of proteasom inhibitor MG132 (50 µM).
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3. Discussion
3.1. Heat-Mediated Inhibition of HR from an Evolutionary Perspective
In the context of cancer treatment, hyperthermia is an effective method to increase anti-cancer
efficacy of DNA-damaging treatments, such as radiotherapy and some forms of chemotherapy [67].
However, in the 19th century, hyperthermia was applied as an anti-cancer treatment in a substantially
different way—patients were treated with bacterial toxins that induced fever [68,69]. This treatment
can be regarded as hyperthermia treatment, as well as immunotherapy—and underlining that fever, an
increase in the core temperature of an organism, is a physiological situation during which hyperthermia
occurs. Interestingly, fever is conserved in both warm-blooded and cold-blooded vertebrates, and has
several very important effects on the immune system [70]. Considering fever and the fever-regulated
response from this evolutionary and physiological perspective sheds a different light on the relevance
of BRCA2 degradation upon hyperthermia. It could be speculated that it is not the downregulation of
BRCA2 in the fever temperature range that is important per se, but the functional effect of it—attenuation
of HR.
From an evolutionary point of view, downregulating HR during fever could have an advantage
for the organism. Fever is part of the immune response that usually occurs when a foreign particle
has infiltrated the body, and we could therefore hypothesize that a concurrent downregulation of HR
might protect the organism against these foreign particles. Indeed, it is known that some viruses hijack
DNA damage repair pathways to replicate their own genomes, and there are examples of viruses, such
as Epstein-Barr and human papillomaviruses, which employ HR proteins to do so [71–73]. However,
for now, this hypothesis remains a mere speculation. It would be interesting to examine whether
BRCA2 orthologues other than humans and mice, such as primates [74] or chicken [75], are also
degraded upon heat treatment. The latter species could yield valuable information about this possibly
conserved response, because birds have a higher basal body temperature than mammals, but can still
get fever [76].
3.2. BRCA2 Protein Stability, HSP90, and Cycloheximide
BRCA2 is expressed in the S and G2 phases of the cell cycle, and BRCA2-transcription peaks
at the start of the S phase [51,52]. Although the half-life of BRCA2 is not precisely known, it is
clear that it is severely shortened by heat. The exact difference in this half-life cannot be determined
by the straightforward application of cycloheximide, as this translation inhibitor protects BRCA2
from degradation. There are at least two explanations for this effect. Firstly, cycloheximide prevents
translation of a certain factor which is rapidly synthesized upon hyperthermia, which could be necessary
for mediating BRCA2 degradation. Secondly, cycloheximide prevents synthesis of many nascent
polypeptides that rely on HSPs to be properly folded, thereby allocating more HSPs to chaperone
unstable proteins, including BRCA2 [77]. Given that the protection provided by cycloheximide is
partly dependent on HSP90 (Figure 3A), the latter hypothesis seems more likely.
3.3. HSP90 Is an Attractive Target to Modulate Heat-Induced BRCA2 Degradation
Hyperthermia-mediated degradation of BRCA2, localization defects of RAD51, and sensitivity
to irradiation are all enhanced by the addition of 17-DMAG or ganetespib [21,31]. There is evidence
that HSP90 influences the steady-state level of BRCA2 by affecting both BRCA2 synthesis as well
as degradation in hyperthermic conditions. The previous demonstration that BRCA2 levels decline
when cells are treated with an HSP90-inhibitor for a prolonged period of time, indicates that HSP90 is
important for BRCA2 homeostasis [30]. By combining cycloheximide with ganetespib, we provide
evidence for the importance of HSP90 in preventing BRCA2 degradation. The BRCA2 protein signal
observed after treatment with cycloheximide represent molecules, which existed prior to treatment with
hyperthermia and ganetespib, dramatically reduces these protected BRCA2 molecules in hyperthermic
conditions (Figure 3A). Thus, HSP90 is not only important for the proper folding of newly synthesized
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BRCA2, but also protects unfolding molecules from being degraded. Therefore, HSP90 is currently
among one of the most attractive targets to modulate heat-induced BRCA2 degradation and to increase
hyperthermia treatment efficacy.
3.4. Ubiquitination May Not Be Required for Heat-Mediated BRCA2-Degradation by the Proteasome
BRCA2 degradation upon heat is mediated by the proteasome, and the most common pathway for
targeting proteins to the proteasome involves the ubiquitin system [78]. Indeed, we demonstrated that
inhibition of the ubiquitin-selective valosin-containing protein (VCP) segregase prevents degradation,
and we found ubiquitin enrichment in immunoprecipitates of the BRCA2-complex shortly after
hyperthermia induction (Table 1), both of which are indications that BRCA2 degradation might be
regulated via ubiquitination. However, our efforts to determine which ubiquitin enzymes might be
involved in this process were not successful (Figures 4 and 5). One E3-ligase we have not specifically
tested as a candidate, but which might be important in BRCA2 regulation, is KEAP1. This protein is
detected in the proteomic screen as an interactor of BRCA2, and has previously been associated with the
complex [47]. However, we did not observe any difference in efficiency of BRCA2 degradation when
we added the neddylation inhibitor MLN4924, which inhibits all cullin-based E3-ligases, including
KEAP1 [46,79] (Figure 5E).
The negative results of the E2- and E3-screens can be interpreted in a number of ways. Our screens
are predominantly based on short-interfering RNA, and insufficient knock-down could therefore
be a problem, considering how low levels of E2 or E3 proteins might be enough to target the lowly
expressed BRCA2 to degradation. Moreover, E2 and E3 enzymes may be redundant. For example,
our finding that both the middle- and C-terminal parts of the BRCA2 protein are heat-labile opens
up the possibility that different E3 enzymes initiate degradation by targeting distinct parts of BCRA2
(Figure 6). However, the key experiment that may explain the inability to find a responsible E2 or E3
ubiquitin enzyme is that inhibition of the E1 enzyme [50], which effectively inhibits the entire ubiquitin
system, still results in degradation of BRCA2 (Figure 5F). Thus, ubiquitination may actually not be
directly involved in hyperthermia-mediated BRCA2 degradation.
Although most proteins are ubiquitinated before being targeted to the common 26S proteasome
form, there is an exception to this rule—proteins may interact with the 26S proteasome via a
ubiquitin-like domain, as is the case for RAD23B [80]. Similarly, it might be that conformational changes
of BRCA2 induced by hyperthermia result in exposure of such a ubiquitin-like domain. There are other
examples of ubiquitin-independent degradation of proteins, but they require a different proteasome
composition. The classic 26S proteasome consists of two 19S regulatory particles which provide
ubiquitin-specificity, while final degradation takes place in the 20S core particle [81]. The assembly of
the proteolytic core itself may change to form the immunoproteasome, which has different proteolytic
activity than the classic 20S core, enabling production of peptides for antigen presentation [82].
Formation of the immunoproteasome is stimulated by the γ-interferon as part of the adaptive immune
response. The proteolytic 20S core can act on its own or be regulated by particles other than the
19S subunit—i.e., the PA200 and the 11S/PA28αβ subunits [82,83]. The PA200 regulatory subunit is
specialized in degrading acetylated histones, and is therefore an example of a ubiquitin-independent
form of the proteasome [84]. The PA28αβ regulators are involved in the degradation of oxidatively
damaged proteins, as is the immunoproteasome [85]. Examples of proteins that may be degraded by
the 20S proteasome on its own are proteins with intrinsically disordered domains which are degraded
“by default” [86], or proteins which are oxidized [87].
Several properties of BRCA2 make it a likely candidate for degradation by a ubiquitin-independent
proteasome. For instance, the ubiquitin-independent degradation “by default” pathway, mediated by
the 20S proteasome, is hypothesized to act on proteins that expose intrinsically disordered domains
after losing interactions with other components of the protein complex in which they normally
reside [86]. BRCA2 is indeed predicted to have intrinsically disordered domains, and may drastically
change conformation upon temperature changes [53]. Furthermore, well-known interactors of BRCA2,
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PALB2 [88,89], and RAD51 [26,90] are not degraded upon heat (Figure 1D) [21], suggesting that BRCA2
is released from complexes with these proteins before being degraded. Oxidative stress may also be
important for heat-mediated BRCA2 degradation via the 20S proteasome, immunoproteasome, or
PA28αβ proteasomes, as illustrated by the effects of oxidative stress on BRCA2 stability (Table 1).
Experimental possibilities to distinguish between the 20S proteasome and the ubiquitin-dependent
26S proteasome are limited. Proteasome inhibitors, including MG132, inhibit both the 20S and 26S
proteasome pathways. However, one way to distinguish between 20S and 26S proteasome activity
is by depleting Adenosine triphosphate (ATP), because the 26S is dependent on ATP, while the 20S
is not [91]. This may, however, have severe consequences for cell viability in general, and may
therefore not be an optimal approach. Other experiments that could elucidate the type of proteasome
required for heat-mediated BRCA2-degradation involve selectively knocking down or inhibiting the
immunoproteasome, the 19S regulatory particle, or the PA28αβ subunit, which can be achieved by
siRNA [85,91].
3.5. BRCA2 and the Oxidative Stress Response
In the proteomic screen aimed at the identification of BRCA2-interactors upon hyperthermia, we
identified HSPB1 as an interactor which dramatically increases in abundance shortly after hyperthermia
induction. We also identified KEAP1 as a constitutive part of the complex (Table 1). Interestingly, these
proteins are currently considered to function in the oxidative stress response. Since cellular response to
hyperthermia and oxidative stress have many similarities [57,92,93], and since important players of the
HR machinery have been associated with the oxidative stress response [47,94], we performed a screen
with a limited number of ROS-inducing agents, as well as antioxidants, and analyzed their effects
on BRCA2. Our data indicate that the level of BRCA2 is in fact decreased in response to oxidative
stress, while radical scavengers can protect BRCA2, to a certain extent, from hyperthermia-mediated
degradation (Figure 7). It is tempting to speculate that hyperthermia-induced BRCA2 degradation
is at least partly dependent on oxidative stress. Notably, BRCA1 and PALB2, both well-established
BRCA2-interactors, are involved in the oxidative stress response [47,94]. Oxidative stress may cause
dissociation of these proteins from the complex, resulting in destabilization of BRCA2.
4. Materials and Methods
4.1. Cell Culture
HeLa, BRO, and U2OS cells were maintained as previously described [21], as were BRCA2GFP/GFP
and the parental wild-type (IB10) mouse embryonic stem cells (mES) [26]. The human ovarian
carcinoma cells UWB-1.289 with and without wtBRCA1 were kindly provided by Dr. Helleman of
the Department of Medical Oncology of the Erasmus University Medical Center, and cultured as
described [95].
4.2. Generation of Constructs and Cell Lines
A full list of constructs and oligonucleotides used in this study can be found in Tables 2
and 3. A step-wise description of engineering the GFP-BRCA2 encoding plasmid has been
provided previously [26]. The BRCA2 fragments used in this study were engineered in a similar
fashion—stepwise Gibson assembly [96] was used to engineer the pGb-LPL vector by replacing
the gene trap cassette of a 5’-PTK-3’ PiggyBac vector [54] with a puromycin acetyltransferase
expression cassette with a phosphoglycerate kinase (PGK) promotor, and a bovine growth hormone
polyadenylation signal from pCAGGS-Dre-IRES-puro [97]. GFP-tagged constructs were engineered by
inserting the following elements into the pGb-LPL vector: a BRCA2-expression cassette consisting
of a CAG promotor, consisting of (C) the cytomegalovirus (CMV) early enhancer element, (A) the
promoter, the first exon and the first intron of chicken beta-actin gene, (G) the splice acceptor of
the rabbit beta-globin gene, from pCAGGS-Dre-IRES-puro [97], an Enhanced Green Fluorescence
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Protein (EGFP)-coding sequence (Takara Bio), and the indicated BRCA2 fragment (using primer
set 1, 2 and 3), amplified from a human BRCA2-coding sequence, phCMV1-MBPx2-hBRCA2 [98].
FLAG-BRCA2 sequences were engineered by inserting the SV40-polyadenylation signal and
cytomegalovirus (CMV)-sequence from phCMV1-MBPx2-hBRCA2, as well as a 3xFLAG sequence
from pR6K-2T1-2PreS-mVenus-Biotin-T2A-gb3-neo, and the indicated BRCA2 fragment (using primer
sets 4, 5, and 6) in the pGb-LPL vector. The FLAG-BRCA2 construct was generated by excising the
eGFP-fragment from the GFP-BRCA2-plasmid using uniquely cutting restriction enzymes and restoring
the excised part with a PCR-generated patch (using primer set 7) containing the 3xFLAG-sequence
and part of the N-terminus of BRCA2 from FLAG-BRCA2-Nterm. FLAG-BRCA2∆M was generated
by excising the sequence coding for the middle part using uniquely cutting restriction enzymes. The
sequence adjacent to the middle part that was included in excision, was restored by a PCR-generated
patch (using primer set 8) from the original construct. All PCR-fragments amplified during plasmid
engineering, as well as the cloning junctions, were verified by sequencing. As described previously for
the GFP-BRCA2 construct [26], stable cell-lines were created by co-transfecting 1 µg of construct with 1
µg PiggyBac transposase expression construct (mPB) per 6-well plate, using the X-tremeGENE HP
DNA transfection reagent (Roche). 1 d after transfection, the selection process began by exposure to
1.5 µg/mL puromycin (Invivogen) for 10 days. The resulting puromycin-resistant cells were assayed as
a mixed population.
Table 2. List of constructs.
Name BRCA2-region(Amino Acid)
Molecular
Weight (kDa) Vector Pro-Motor Code/Ref
FLAG-BRCA2 Met 1–Ile 3418 382 pGb-LPL CAG pAZ148
GFP-BRCA2 Met 1–Ile 3418 406 pGb-LPL CAG pAZ114 [26]
BRCA2-N-GFP Met 1–Thr 939 131 pGb-LPL CAG pAZ108
BRCA2-M-GFP Gln 940–Glu 2198 167 pGb-LPL CAG pAZ109
BRCA2-C-GFP Thr 2199–Ile 3418 162 pGb-LPL CAG pAZ110
FLAG-BRCA2-N Met 1–Thr 939 107 pGb-LPL CMV pAZ97
FLAG-BRCA2-M Gln 940–Glu 2198 123 pGb-LPL CMV pAZ98
FLAG-BRCA2-C Thr 2199–Ile 3418 118 pGb-LPL CMV pAZ104
FLAG-BRCA2-∆M Met 1–Thr 939Thr 2199–Ile 3418 250 pGb-LPL CAG pAZ253
Clover-HSP90 n.a. 109 pGb-LPL CAG n.a.
FLAG-HSP90 n.a. 82 pGb-LPL CMV [99]
Table 3. List of oligonucleotides used in this study.
Set Name Sequence
1F GA15N-F 5’-GCTCCTGGGCAACGTGCCTCGAGATGCCTATTGGATCCAAAGAGAGGCCAAC-3’
1R GA15N-R 5’-TTGCTCACCATGGTGGCCTCGAGGGTTGCTTGTTTATCACCTGTGT-3’
2F GA15M-F 5’-GCTCCTGGGCAACGTGCCTCGAGATGCAAGTGTCAATTAAAAAAGATTTGGTTTATGTTCTTGC-3’
2R GA15M-R 5’-TTGCTCACCATGGTGGCCTCGAAAGTTTCAGTTTTACCAATTTCCATTTTTACGTT-3’
3F GA15C-F 5’-GCTCCTGGGCAACGTGCCTCGAGATGACTTTTTCTGATGTTCCTGTGAAAACAAATATAGAAG-3’
3R GA15C-R 5’-TTGCTCACCATGGTGGCCTCGAGGATATATTTTTTAGTTGTAATTGTGTCCTGCTTATTTTTCTCACA-3’
4F BRCA2-Nterm-F 5’-CAAGGATGACGACGACAAGAGCCCTATTGGATCCAAAGAGAGGC-3’
4R BRCA2-Nterm-R 5’-GCTGATTATGATCTAGAGTCAGGTTGCTTGTTTATCACCTGTGTCT-3’
5F GA04M-F 5’-CAAGGATGACGACGACAAGAGATCTACCCAAGTGTCAATTAAAAAAGATTTGGTTTATGT-3’
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Table 3. Cont.
Set Name Sequence
5R GA04M-R 5’-GCTGATTATGATCTAGAGTCAGATCTTTTCAGTTTTACCAATTTCCATTTTTACGTTTTTAGGT-3’
6F GA04C-F 5’-CAAGGATGACGACGACAAGAGATCTACTTTTTCTGATGTTCCTGTGAAAACAAATATAGAAG-3’
6R GA04C-R 5’-GCTGATTATGATCTAGAGTCAGATCTTTAGATATATTTTTTAGTTGTAA TTGTGTCCTGCTTATTTTTCTCACAT-3’
7F B2flFLAG-F1 5’-CCTGGGCAACGTGCCGATTATAAAGACCACGATGGAGACTATAAAGATCATGACATTGACT-3’
7R B2flFLAG-R2 5’-CACTGTCCTTCCTGCAGGCATGACAGAGAA-3’
8F B2intdel-GA-F1 5’-TTCTCTGTCATGCCTGCAGGAAGGAC-3’
8R B2intdel-GA-R1 5’-CAACATTTAAGTTATTTGATAATTTGGTTGCTTGTTTATCACCTGTGTCT-3’
4.3. Hyperthermia Treatment
The time designated for effective hyperthermia treatment started 15 min (referred to as pre-heating
time) after moving the cells to an incubator set at 42 ◦C. Unless stated otherwise, cells were treated
with 60 min of hyperthermia.
4.4. Chemical Agents and UV Irradiation
Cells were UV-irradiated with Ultraviolet (UV)-B (2 TL-12 (40W) tubes, Philips) at the indicated
doses. A full list of used chemical agents and suppliers can be found in Table 4. Unless stated otherwise,
inhibitors were added to the medium 30–60 min prior to hyperthermia and left on the cells for the
duration of the treatment. Cells were treated with antioxidants and oxidative-stress-inducing agents in
Hank’s Balanced Salt Solution (Gibco®HBSS, Thermo Fisher). Antioxidants were added directly prior
to hyperthermia, while treatment with the oxidative-stress-inducing agents lasted 75 min.
Table 4. List of used chemicals.
Name Reference/Suppliers
Bafilomycin Sigma-Aldrich
NMS-873 Selleckchem
Ganetespib Syntha Pharmaceuticals
MG132 Merck Millipore
Cycloheximide Sigma-Aldrich
MLN4924 MedChem Express
PYR-41 Calbiochem
NAC Sigma-Aldrich
Ascorbic Acid Sigma-Aldrich
DTT Sigma-Aldrich
H2O2 Sigma-Aldrich
t-BHP Sigma-Aldrich
Rotenone MP Biomedicals
4.5. siRNA Transfection
A full list of used siRNAs with suppliers and references can be found in Table 5. Cells
were transfected with a final concentration of 60 nM siRNAs using Lipofectamine RNAiMAX (Life
Technologies). The systematic E2 screen was performed as previously described [37]. Experiments
were performed 48–72 h after transfection.
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Table 5. List of siRNAs.
siRNA SenseSequence Reference/Suppliers
Luc CGUACGCGGAAUACUUCGA Thermo Scientific
siAKTIP#1 GAAUUUACCUUGGUUGUGA [37]
siAKTIP#2 AGAAAACAGUGGCGACUUA [37]
siBIRC6#1 UCAUUGCCUUACUCACAUA [37]
siBIRC6#2 GGUCAAAGAUCACUUAGUA [37]
siTSG101#1 AGUAGCCGAGGUUGAUAAA [37]
siTSG101#2 AAACUGAGAUGGCGGAUGA [37]
siUBE2A#1 UGAUGUGUCUUCCAUUCUA [37]
siUBE2A#2 GAUGAACCCAAUCCCAAUA [37]
siUBE2B#1 AUAGACAACUGGUCUGUUA [37]
siUBE2B#2 UUGGACCAGAAGGGACACC [37]
siUBE2C#1 GCAAGAAACCUACUCAAAG [37]
siUBE2C#2 UAAAUUAAGCCUCGGUUGA [37]
siUBE2D1#1 UACUGUAUGUGUUGUCUAA [37]
siUBE2D1#2 CAACAGACAUGCAAGAGAA [37]
siUBE2D2#1 CAGUAAUGGCAGCAUUUGU [37]
siUBE2D2#2 CCAACCAGAUUAAACUCUA [37]
siUBE2D3#1 UGAUGUAAAGUUCGAAAGA [37]
siUBE2D3#2 CCACAAUUAUGGGACCUAA [37]
siUBE2D4#1 CAGCGUUGACUGUGUCAAA [37]
siUBE2D4#2 GGAAUUAACCGACUUGCAG [37]
siUBE2E1#1 GCGAUAACAUCUAUGAAUG [37]
siUBE2E1#2 GGUGUAUUCUUUCUCGAUA [37]
siUBE2E2#1 ACUUGAAAGAUUUGGGAUU [37]
siUBE2E2#2 UCACCAGACUAUCCGUUUA [37]
siUBE2E3#1 GCAUAGCCACUCAGUAUUU [37]
siUBE2E3#2 GCUAAGUUAUCCACUAGUG [37]
siUBE2F#1 GGAAUAAAGUGGAUGACUA [37]
siUBE2F#2 CAACAUAAAUACAGCAAGA [37]
siUBE2G1#1 UGUUGAUGCUGCGAAAGAA [37]
siUBE2G1#2 GGGAAGAUAAGUAUGGUUA [37]
siUBE2G2#1 AUGAUGACUUAAUGUCGAA [37]
siUBE2G2#2 UGACGAAAGUGGAGCUAAC [37]
siUBE2H#1 CGAGAGUAAACAUGAGGUU [37]
siUBE2H#2 CUACUGAACUGUCGAAGGA [37]
siUBE2J1#1 GAACUGGCUAGGCAAAUAA [37]
siUBE2J1#2 GAAAGAAGCGGCAGAAUUG [37]
siUBE2J2#1 GAAGGUGGCUAUUAUCAUG [37]
siUBE2J2#2 GCACAAGACGAACUCAGUA [37]
siUBE2K#1 CUCUCCGCACGGUAUUAUU [37]
siUBE2K#2 GAAUCAAGCGGGAGUUCAA [37]
siUBE2L3#1 UGAAGAGUUUACAAAGAAA [37]
siUBE2L3#2 GGGCUGACCUAGCUGAAGA [37]
siUBE2L6#1 UGAUCAAAUUCACAACCAA [37]
siUBE2L6#2 UCAAUGUGCUGGUGAAUAG [37]
siUBE2M#1 AGCCAGUCCUUACGAUAAA [37]
siUBE2M#2 GAUGAGGGCUUCUACAAGA [37]
siUBE2N#1 GCGGAGCAGUGGAAGACCA [37]
siUBE2N#2 CUAUCUAGCUUGUGUGUCA [37]
siUBE2NL#1 AAACGUGAACUAUUACUUG [37]
siUBE2NL#2 GACAAGUUGGAAAGAAUAA [37]
siUBE2O#1 ACAUCGACUGUGCCGUCAA [37]
siUBE2O#2 GGGACUACAUUGCCUAUGA [37]
siUBE2Q1#1 UCAUCUCCGACCUGUGUAA [37]
siUBE2Q1#2 GAAAGGGAAUACUCUGCUA [37]
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Table 5. Cont.
siRNA SenseSequence Reference/Suppliers
siUBE2Q2#1 UACAGAUCACAGAGUUAUA [37]
siUBE2Q2#2 GUAUGGAACUUCUCACAAA [37]
siUBE2R1#1 CGCAGAACGUCAGGACCAU [37]
siUBE2R1#2 GGAAGUGGAAAGAGAGCAA [37]
siUBE2R2#1 UGUGAGGACUAUCCUAUUA [37]
siUBE2R2#2 CCACAACCCUGGCGGAAUA [37]
siUBE2S#1 AUGGCGAGAUCUGCGUCAA [37]
siUBE2S#2 ACAAGGAGGUGACGACACU [37]
siUBE2T#1 AGAGAGAGCUGCACAUGUU [37]
siUBE2T#2 CCUGCGAGCUCAAAUAUUA [37]
siUBE2U#1 ACAGGCCAUUACAAAUGAA [37]
siUBE2U#2 GAAGUGGAAUACAAACUAU [37]
siUBE2V1#1 GGACAGUGUUACAGCAAUU [37]
siUBE2V1#2 GUGGAUGCAUACCGAAAUA [37]
siUBE2V2#1 AGUUGUACUUCAAGAGCUA [37]
siUBE2V2#2 GUUAAAGUUCCUCGUAAUU [37]
siUBE2W#1 CGACCACCGGAUAAUUCUU [37]
siUBE2W#2 GCGAACAUGUAACAAGAAU [37]
siUBE2Z#1 AUGUUCGUUGUACCUGAUA [37]
siUBE2Z#2 GGGAAAGUCUGCUUGAGUA [37]
siUEV3#1 CGAUGGACCUUGAAAUCUU [37]
siUEV3#2 AGAAAGACCUGCUGAAUUU [37]
UBC9 GGGAUUGGUUUGGCAAGAA [39]
CHIP#1 GCGCUCUUCGAAUCGCGAAGA Invitrogen
CHIP#2 UGCCGCCACUAUCUGUGUAAU Invitrogen
PIAS1 GGAUCAUUCUAGAGCUUUA [43]
PIAS2 CUUGAAUAUUACAUCUUUA [43]
PIAS3 CCCUGAUGUCACCAUGAAA [43]
PIAS4 GGAGUAAGAGUGGACUGAA [43]
RNF4#1 GAAUGGACGUCUCAUCGUU [39]
RNF4#2 GACAGAGACGUAUAUGUGA Thermo Scientific
RNF111 GGAUAUUAAUGCAGAGGAA [39]
4.6. Immunoprecipitation
For each immunoprecipitation, cells were prepared in a 15 cm dish at 70–80% confluency. After
treatment, cells were washed twice in ice-cold PBS and lysed for 30 min on ice in NETT buffer (100 mM
NaCl, 50 mM Tris pH 7.5, 5 mM ethylenediaminetetraacetic acid (EDTA) pH 8.0, 0.5% Triton-X100, 1x
protease inhibitors (Complete, Roche®) and 1 mM pefabloc). Anti-Green Fluorescence Protein (GFP)
beads (Chromotek) were prepared according to the manufacturer’s protocol. After scraping the cells,
the suspensions were centrifuged (12000 rcf, 15 min), and the resulting supernatant (input) was added
to the beads and incubated for 4 h, rotating at 4 ◦C. The immunoprecipitation was completed according
to the manufacturer’s protocol.
4.7. Cell Fractionation, Lysis, and Immunoblotting
The cell fractionation was performed as described for immunoprecipitations. The pellet and
supernatant resulting from the centrifugation step were analyzed. Cell lysis and immunoblotting were
performed as described previously [22], with the exception of gel type, which included acrylamide,
3–8% Tris-Acetate gels (Novex, Thermofisher Scientific) or 4–20% TGXTM-gels (Biorad), and blotting
membrane, which included both PVDF and nitrocellulose.
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4.8. Immunofluorescent Staining and Analysis of RAD51-Foci
Cells were treated with hyperthermia and subsequently irradiated with a caesium-137 source with
a dose rate of 0.64 Gy/min. EdU (Invitrogen) was added to the cells 45 min prior to fixation to identify
S-phase cells. Cells were fixed 1.5 h after irradiation. Cell fixation, immunofluorescent staining, and
image acquisition and analysis were performed as described in [22].
4.9. Antibodies
A full list of antibodies and used dilutions can be found in Table 6.
Table 6. List of antibodies.
Host Epitope Dilutions Used Reference/Suppliers
Mouse BRCA2 (OP95) WB 1:1000 EMD Millipore
Mouse FLAG (M2) WB 1:1000–1:5000 Sigma-Aldrich
Mouse ORC2 (68348) WB 1:1000 Abcam
Rabbit Brca2 (27976) WB 1:500 Abcam
Mouse GFP (clones 7.1 and 13.1) WB 1:1000–1:5000 Sigma-Aldrich
Mouse PARP-1 (C2-10) WB 1:5000 Enzo Lifesciences
Mouse BRCA1 (OP92) WB 1:250 EMD Millipore
Rabbit Cyclin A (C-19) WB 1:5000 Santa Cruz
Goat RAD54 (D-18) WB 1:1000 Santa Cruz
Rabbit RAD51 (2307) WB 1:10,000 Home-made [100]
Rabbit RAD51 (2308) IF 1:10,000 Home-made [100]
Mouse GRB2 WB 1:1000 BD Pharmingen
Mouse HSP90 (AC88, 13492) WB 1:5000 Abcam
Rabbit CDC37 (3618S) WB 1:1000 Cell Signaling
Goat UBC9 (N-15) WB 1:1000 Santa Cruz
Rabbit CHIP (PA1-015) WB 1:1000 Thermo Scientific
Sheep Peroxidase anti-Mouse IgG (H+L) WB 1:2000 Jackson Immunoresearch
Donkey Peroxidase anti-Rabbit IgG (H+L) WB 1:2000 Jackson Immunoresearch
Donkey Peroxidase anti-Goat IgG (H+L) WB 1:2000 Jackson Immunoresearch
Goat Alexa-Fluor-594 (red) IF 1:1000 Thermo Scientific
4.10. SILAC-Based Mass Spectrometry
Cells were cultured in DMEM medium without lysine or arginine, and supplemented with
dialyzed serum for two weeks prior to the experiment. Isotopes of L-lysine and L-Arginine (Cambridge
Isotope Laboratories) were added to the medium to label the following three SILAC-states: Light
(K0R0), Medium (K4R6), and Heavy (K8R10). Immunoprecipitations were performed for each state
separately, as described above. As published previously [101], bound proteins of all three states were
mixed after immunoprecipitation and digested “on bead”. Data were analyzed using the Andromeda
Search Engine within the MaxQuant software package, version 1.5.3.8 [102,103].
5. Conclusions
Hyperthermia attenuates HR by downregulating HR proteins, including BRCA2, thereby rendering
innately HR-proficient cells sensitive to PARP inhibitors. Understanding the mechanism by which
hyperthermia targets BRCA2 for degradation is interesting from both a biological and clinical
perspective, because it could yield a general understanding of hyperthermia biology, regulation
of BRCA2 and HR, and eventually unravel other therapeutic targets that may inhibit HR or increase
hyperthermia efficacy [67]. Here, we explored this mechanism and presented molecular details
of hyperthermia-mediated degradation of BRCA2. With regard to BRCA2, we showed that its
heat-induced degradation is evolutionarily conserved, that its stability is guarded by HSP90, that
ubiquitin might not be involved in directly targeting it for protein degradation via the proteasome,
and that its degradation might be modulated by oxidative stress and radical scavengers.
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